<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ILEX ONCOLOGY, INC.
-------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.01
-------------------------------
(Title of Class of Securities)
451923-10-6
-------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement. (A fee is
not required only if the filing person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
[ ]
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP No. 451923-10-6 13G Page 2 of 4 Pages
- --------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CTRC Research Foundation; Tax I.D.: 74-2618443
- --------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [x]
- --------------------------------------------------------------------------------
3. SEC USE ONLY
- --------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Texas
- --------------------------------------------------------------------------------
5. SOLE VOTING POWER
2,782,127
NUMBER OF ------------------------------------------------------
SHARES 6. SHARED VOTING POWER
BENEFICIALLY
OWNED BY None
EACH
REPORTING -------------------------------------------------------
PERSON 7. SOLE DISPOSITIVE POWER
WITH
2,782,127
-------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
- --------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,782,127
- --------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [ ]
- --------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
22.7%
- --------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS
Page 2 of 4 Pages
<PAGE> 3
CUSIP No. 451923-10-6 13G Page 3 of 4 Pages
ITEM 1.
(a) (b) This statement on Schedule 13G relates to the Reporting
Person's (as defined in Item 2 below) beneficial ownership interest in ILEX
Oncology, Inc., a Delaware corporation (the "Issuer"). The address of the
principal executive office of the Issuer is 11550 I.H. 10 West, Suite 300, San
Antonio, Texas 78230.
ITEM 2.
(a) This statement is being filed by CTRC Research Foundation (the
"Reporting Person");
(b) The principal business address of the Reporting Person is 8122
Datapoint Drive, Suite 600, San Antonio, Texas 78229.
(d) (e) This statement relates to the Common Stock, par value $0.01
per share (the "Common Stock"), of the Issuer named in Item 1 of this
statement. The CUSIP number associated with such Common Stock is 451923-10-6.
ITEM 3. FILING PURSUANT TO RULE 13d-1(b), OR 13d-2(b).
This statement is not being filed pursuant to Rule 13d-1(b) or
13d-2(b).
ITEM 4. OWNERSHIP.
(a) (b) The aggregate number of shares of the Common Stock
beneficially owned by the Reporting Person is 2,782,127, which represents 22.7%
of the shares of Common Stock reported to be outstanding in the Quarterly
Report on Form 10-Q of the Issuer for the quarter ended September 30, 1997.
The aggregate number and percentage of the Common Stock beneficially owned by
the Reporting Person is calculated in accordance with Rule 13d-3(d)(1).
(c) The Reporting Person has sole voting and dispositive power over
the Common Stock beneficially owned by it as indicated above.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not Applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not Applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not Applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not Applicable.
Page 3 of 4 Pages
<PAGE> 4
CUSIP No. 451923-10-6 13G Page 4 of 4 Pages
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not Applicable.
ITEM 10. CERTIFICATION.
Not Applicable.
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief,
we certify that the information set forth in this statement is true, complete
and correct.
March 30, 1998
CTRC RESEARCH FOUNDATION
By: /s/ David C. Spoor
--------------------------------------
David C. Spoor, Vice President and
General Counsel
Page 4 of 4 Pages
